Evidence map›Paper›PMID 41704423›Full record

ArticleJHEP reports : innovation in hepatology2026

Soluble urokinase plasminogen activator receptor is a prognostic biomarker in decompensated cirrhosis.

Sven Lamatsch, Mohsin Hassan, Kai Kappert, Hilmar Berger, Qingquan Bai, Zhengyang Zhao, Nirbaanjot Walia, Carlos De La Peña-Ramirez, Raphael Mohr, Münevver Demir and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Sven LamatschCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hepatology & Gastroenterology, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany.
Mohsin HassanCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hepatology & Gastroenterology, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany.
Kai KappertCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Diagnostic Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Berlin, Germany.
Hilmar BergerCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hepatology & Gastroenterology, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany.
Qingquan BaiCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hepatology & Gastroenterology, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany.
Zhengyang ZhaoCancer Research Center, School of Medicine, Xiamen University, Xiamen, China.
Nirbaanjot WaliaCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hepatology & Gastroenterology, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany.
Carlos De La Peña-RamirezEuropean Foundation for the Study of Chronic Liver Failure, Barcelona, Spain.
Raphael MohrCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hepatology & Gastroenterology, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany.
Münevver DemirCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hepatology & Gastroenterology, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany.
Juan WangCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hepatology & Gastroenterology, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany.
Fabian ArtusaCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hepatology & Gastroenterology, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany.
Richard SittnerCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hepatology & Gastroenterology, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany.
Fausto AndreolaLiver Failure Group, Institute for Liver and Digestive Health, University College London Medical School, Royal Free Hospital, London, United Kingdom.
Rhea VeelkenLeipzig University Medical center, Division of Hepatology, Department of Medicine II, Leipzig, Germany.
Florian van BoemmelLeipzig University Medical center, Division of Hepatology, Department of Medicine II, Leipzig, Germany.
Jonas SchumacherLeipzig University Medical center, Division of Hepatology, Department of Medicine II, Leipzig, Germany.
Niklas AehlingLeipzig University Medical center, Division of Hepatology, Department of Medicine II, Leipzig, Germany.
Janett FischerLeipzig University Medical center, Division of Hepatology, Department of Medicine II, Leipzig, Germany.
Rajeshwar MookerjeeLiver Failure Group, Institute for Liver and Digestive Health, University College London Medical School, Royal Free Hospital, London, United Kingdom.
Tianhui HuCancer Research Center, School of Medicine, Xiamen University, Xiamen, China.
Thomas BergLeipzig University Medical center, Division of Hepatology, Department of Medicine II, Leipzig, Germany.
Rajiv JalanLiver Failure Group, Institute for Liver and Digestive Health, University College London Medical School, Royal Free Hospital, London, United Kingdom.
Frank TackeCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hepatology & Gastroenterology, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany.
Pavitra KumarCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hepatology & Gastroenterology, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany.
Cornelius EngelmannCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hepatology & Gastroenterology, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: Cirrhosis poses a significant healthcare burden, with decompensation and acute-on-chronic liver failure (ACLF) resulting in high morbidity and mortality. Reliable biomarkers of disease progression are urgently needed. Urokinase plasminogen activator receptor (uPAR) and its soluble form (suPAR) are linked to systemic inflammation in liver disease. This study aims to evaluate suPAR as a prognostic marker and its role in chronic liver disease. Methods: SuPAR levels were measured in a derivation cohort (n = 178) and a validation cohort (n = 197) from two centers, including healthy controls and patients with cirrhosis, acute decompensation, and ACLF. In a mouse model using carbon tetrachloride and lipopolysaccharide, suPAR levels correlated with liver uPAR expression. Single-cell RNA sequencing was used to analyze uPAR expression in immune cells from healthy controls and from patients with HBV-related cirrhosis. Results: SuPAR levels correlated with disease severity markers, including creatinine, bilirubin, albumin, international normalized ratio, MELD score, and hospitalization duration (all Conclusions: SuPAR is a potential biomarker for predicting outcomes in acute decompensation, reflecting both systemic and liver-specific inflammation. Further studies are needed to clarify the role of uPAR-expressing cells in disease progression. Impact and implications: Our study identifies soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of liver-derived systemic inflammation that is clinically relevant for predicting adverse outcomes in decompensated cirrhosis and is associated with disease progression, organ dysfunction, and mortality. Systemic suPAR levels ≥14.0 ng/ml independently predicted 90-day mortality in patients with decompensated cirrhosis across two independent cohorts. Accurate outcome prediction is crucial for developing tailored, personalized treatments in advanced chronic liver disease, and suPAR, as an independent predictor of short-term mortality and disease progression, may complement established scoring systems such as MELD.

Indexed as

ACLFBiomarkerChronic liver diseaseCirrhosisPLAURsuPAR

Identifiers

PMID41704423
PMCPMC12907094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.